Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Background The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with
acute ischemic stroke but who have no evidence of complete occlusion of large or medium …

Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein (GP) IIb/IIIa
inhibitors, have proved to be successful in reducing the morbidity and mortality associated …

Four major receptor families enable cells to respond to chemical and physical signals from
their proximal environment. The ligand-and voltage-gated ion channels, G-protein-coupled …

One of the earliest and best-recognized elements of atherosclerosis is its close relationship
with circulating LDL (low-density lipoprotein). There is convincing evidence that LDL …

C-reactive protein (CRP) is a predictor of cardiovascular risk. It circulates as a pentamer
(pentameric CRP) in plasma. The in vivo existence of monomeric (m) CRP has been …

Tirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly
inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi …

Acute myocardial infarction (AMI) is the single leading cause of mortality and morbidity
worldwide. A key component of AMI therapy is the timely reopening of occluded vessels to …

In vivo mouse models have indicated that the intrinsic coagulation pathway, initiated by
factor XII, contributes to thrombus formation in response to major vascular damage. Here, we …